The Platform Redevelopment Powering the Future of MS Treatment 

To improve treatment and one day find a cure for Multiple Sclerosis (MS), the not-for-profit MSBase Foundation created the MSBase Registry (MSBase) – an international online registry that facilitates the collection, tracking, sharing and evaluation of real-world MS patient data in specialist clinical practice, providing resources that enable long-term outcomes research to inform and improve patient care. 

Svitla architected, developed, and delivered a full end-to-end, Microsoft technology-stack web-based research registry application to replace the old MSBase.

Launched in 2017, the new solution incorporates several improvements and usability enhancements, which resolve the limitations experienced by the Foundation:  

• It now accepts multiple inputs and uses the Internet of Things (IoT) to interface with multiple devices, such as MRI machines  

• It provides the Foundation control over the direction of the product  

• It allows the end user to search, report, and visualize data  

• It’s easily customized to respond to new sub-studies  

• It provides an environment where information sharing and synchronization are encouraged 

• It’s repeatable and can be readily adopted in virtually any research and data capture scenario globally. 

The significance of the new MSBase is that the Foundation is now involved in a world-first endeavor, integrating volumetric MRI metrics directly into MSBase via IoT. This ambitious, large-scale project will use the collated MRI measures to develop a marker to predict disease progression, enabling early detection of worsening disease and early implementation of preventive measures, such as treatment changes, which can drastically improve outcomes for people living with MS.  

The global database of MS patients can now also participate in observational trials, which are activated through an innovative sub-study platform. In each study, selected sets of disease characteristics are mapped prospectively, allowing investigators to conduct research analyses and pharmaceutical companies to assess the medium- and long-term effects and safety of their products.  

This project has also led to generous grants from Foundation sponsors and to new, ongoing funded projects in MS research, which will ultimately lead to much better outcomes for patients.